Added to YB: 2024-08-28
Pitch date: 2024-06-30
EYPT [bullish]
EyePoint, Inc.
+69.35%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
Market Cap
$1.1B
Pitch Price
$8.68
Price Target
N/A
Dividend
N/A
EV/EBITDA
-4.21
P/E
-4.32
EV/Sales
21.03
Sector
Pharmaceuticals
Category
turnaround
Show full summary:
Franklin Biotechnology Discovery Fund Portfolio Holding: EyePoint Pharmaceuticals, Inc.
EYPT: Phase 2 NPDR trial failed, stock -50%. Still has promising candidates: DURAVYU Phase 3 for wet AMD H2 2024, DME Phase 2 data Q1 2025. Well-financed.
Read full article (1 min)